醫學系婦產學科

Medicine and Dentistry

1. Endometriosis 86%
2. Uterine Cancer 85%
3. Krukenberg Tumor 79%
4. Recurrent Disease 79%
5. Arrhythmogenesis 74%
6. Retrospective Cohort Study 72%
7. Systematic Review 70%
8. Uterine Myomectomy 67%
9. Myoma 66%
10. Adenomyosis 63%
11. Neoplasm 62%
12. Overall Survival 61%
13. Ovarian Cancer 60%
14. Fibroblast 49%
15. Obstetrics 48%
16. Gynecology 48%
17. Cervical Cancer 44%
18. Diseases 44%
19. Gestational Age 43%
20. Pelvis 41%
21. Cystectomy 41%
22. Laparoscopic Surgery 41%
23. Atrial Fibrillation 40%
24. Pregnancy 40%
25. Cisplatin 39%
26. Uterus Sarcoma 39%
27. Induced Pluripotent Stem Cell 39%
28. Calcium Homeostasis 39%
29. Calcium Ion 38%
30. Operation Duration 35%
31. Isotopes of Calcium 34%
32. Clear Cell Carcinoma 34%
33. Cyclooxygenase 2 33%
34. Cytoreductive Surgery 33%
35. Cancer 33%
36. Uterine Fibroid 32%
37. Angiogenesis 31%
38. Bleeding 30%
39. Progression Free Survival 30%
40. Uterine Tube Carcinoma 29%
41. Morcellation 29%
42. Stress Incontinence 29%
43. Endometrium Carcinoma 29%
44. Ventricular Outflow Tract 29%
45. Pulmonary Vein 29%
46. Adenocarcinoma 29%
47. Prognostic Factor 29%
48. Menorrhagia 29%
49. Doppler Flowmetry 27%
50. Doppler Ultrasound 27%
51. Recurrence Risk 27%
52. Dentigerous Cyst 26%
53. First Trimester Pregnancy 26%
54. Adverse Event 25%
55. Randomized Controlled Trial 24%
56. Surgery 23%
57. Gonadorelin Agonist 23%
58. Disease Free Survival 22%
59. Metastatic Carcinoma 22%
60. Endometrium 22%
61. Squamous Cell Carcinoma 22%
62. Breast Cancer 21%
63. Oxidative Stress 21%
64. Mesenchymal-Epithelial Transition 21%
65. Carcinoma 21%
66. Immunohistochemistry 21%
67. Vasculotropin 21%
68. Ovarian Tumor 21%
69. Blood Flow 21%
70. Chronic Kidney Disease 20%
71. Echography 20%
72. Western Blot 20%
73. Carcinosarcoma 19%
74. Gynecological Oncology 19%
75. Epithelial Cell 19%
76. Oncogene C Myc 19%
77. Liver Injury 19%
78. Laparotomy 19%
79. Polycystic Ovary Syndrome 19%
80. Protein P53 19%
81. Oxaliplatin 19%
82. Recurrent Ovarian Cancer 19%
83. Gut 19%
84. Heart Atrium Remodeling 19%
85. Cervix 19%
86. Hepatocyte 19%
87. Postmenopause 18%
88. Paclitaxel 17%
89. Retrospective Study 17%
90. Ifosfamide 17%
91. Carcinogenesis 16%
92. Dienogest 16%
93. Odds Ratio 16%
94. Cardiac Muscle Cell 16%
95. Pulsatility Index 16%
96. Cohort Analysis 16%
97. Proportional Hazards Model 16%
98. Hazard Ratio 16%
99. Left Atrium 16%
100. Congestive Heart Failure 15%

Keyphrases

1. Taiwan 100%
2. Endometriosis 83%
3. Induced Pluripotent Stem Cells (iPSCs) 79%
4. Confidence Interval 64%
5. Taiwanese 64%
6. Retrospective Cohort Study 63%
7. Endometrial Cancer 62%
8. Adenomyosis 61%
9. Epithelial Ovarian Cancer 61%
10. Estrogen 55%
11. Overall Survival 54%
12. Calcium Homeostasis 50%
13. Pulmonary Vein 46%
14. Arrhythmogenesis 45%
15. Myomectomy 41%
16. Fibrogenesis 40%
17. Postmenopausal Women 40%
18. Ovarian Cancer 40%
19. Uterine Sarcoma 39%
20. Laparoscopic Surgery 39%
21. Cervical Cancer 37%
22. Gonadotropin-releasing Hormone 36%
23. Laparoscopic Myomectomy 35%
24. Ovarian Cancer Patients 35%
25. Recurrence Rate 33%
26. Gestational Age 32%
27. Cancer Patients 31%
28. Cisplatin 31%
29. Angiogenesis 31%
30. Operative Time 30%
31. Fallopian Tube Carcinoma 29%
32. Bipolar Coagulation 29%
33. Uterine Vessels 29%
34. Taiwanese Women 29%
35. Single Port 29%
36. Rare Case Report 29%
37. Endometrial Carcinoma 29%
38. Laparoscopic Cystectomy 29%
39. Overexpression 29%
40. Cyclooxygenase-2 28%
41. Obstetrics 27%
42. Advanced Stage 26%
43. Electrical Activity 26%
44. Randomized Controlled Trial 26%
45. Odds Ratio 26%
46. Prognostic Factors 26%
47. Ovarian Clear Cell Carcinoma 24%
48. Adverse Events 24%
49. Power Doppler Ultrasound 24%
50. Mouse Model 23%
51. Normal Pregnancy 23%
52. Agonist Treatment 23%
53. Hazard Ratio 23%
54. Heart Failure 23%
55. Transplantation 23%
56. Levonorgestrel-releasing Intrauterine System (LNG-IUS) 23%
57. Atrial Arrhythmogenesis 22%
58. Laparoscopy 22%
59. Fallopian Tube 22%
60. Progression-free Survival 22%
61. Single-port Laparoscopic 22%
62. Older Women 21%
63. Survival Outcomes 21%
64. Conventional Laparoscopic 21%
65. Stress Urinary Incontinence 21%
66. Human Atrial Fibroblasts 21%
67. Myoma 21%
68. Cyclooxygenase-2 Expression 21%
69. C-Myc 20%
70. Hepatoprotective 20%
71. Uterus 20%
72. Liver Injury 19%
73. Symptomatic Uterine Fibroids 19%
74. Gynecologic Oncology Group 19%
75. Cervical Squamous Cell Carcinoma 19%
76. Invasive Cervical Cancer 19%
77. Ultraminilaparotomy 19%
78. ST6GAL1 19%
79. Parasitic Myoma 19%
80. Laparoscopic Morcellation 19%
81. PRISMA 19%
82. Ovarian Dermoid Cyst 19%
83. Endometrial Epithelial Cells 19%
84. Young Women 19%
85. Endometrioma Recurrence 19%
86. Cisplatin-based Chemotherapy 19%
87. Laparotomy 19%
88. Sialyltransferase 19%
89. Upper Abdominal Pain 19%
90. Gynecological Laparoscopic Surgery 19%
91. Estrogen Receptor 19%
92. Transobturator 19%
93. Laparoscopic Ovarian Drilling 19%
94. Wound Healing 19%
95. Mini 19%
96. Polycystic Ovary Syndrome 19%
97. Round Spermatid Injection 19%
98. Staging System 19%
99. Endometrial Cancer Staging 19%
100. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) 19%